{"id":942276,"date":"2026-03-05T11:56:24","date_gmt":"2026-03-05T16:56:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/"},"modified":"2026-03-05T11:56:24","modified_gmt":"2026-03-05T16:56:24","slug":"wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/","title":{"rendered":"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <em>Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference<br \/><\/em>\n      <\/p>\n<p align=\"left\">CAMBRIDGE, Mass., March  05, 2026  (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic Society (ATS) International Conference taking place in Orlando, Florida during May 15-20, 2026. Wave now expects to share data from the 600 mg single dose cohort in addition to data from the 400 mg multidose cohort at the ATS conference in May.<\/p>\n<p>\u201cThe annual ATS conference is an important forum for fostering innovation in pulmonary care, and we are excited to have the opportunity to share data from our RestorAATion-2 trial, including our upcoming 400 mg multidose data and 600 mg single dose data,\u201d said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. \u201cAATD, a debilitating disease that impacts many aspects of daily life, is well suited for RNA editing because it is a single\u2011gene disorder, where correcting the mutant RNA transcript in the liver directly addresses the root cause of both lung and liver manifestations of the disease. We are advancing regulatory engagement on a potential accelerated approval pathway for WVE-006 and expect feedback mid-2026. Additionally, we remain on track to deliver data from the INLIGHT trial of WVE-007 for obesity this month.\u201d<\/p>\n<p>\n        <strong>Details of the late-breaking oral presentation:<br \/><\/strong>Title: RNA Editing for the Treatment of Alpha-1 Antitrypsin Deficiency<br \/>Session: B101 Decoding Disease: Biomarkers, Phenotypes, and Precision Medicine<br \/>Presenter: Kenneth R. Chapman, MsC, MD, FRCPC, FACP, FERS, Department of Medicine, University of Toronto<br \/>Date and time: Monday, May 18, 2026, 4:03 \u2013 4:15 p.m. ET<\/p>\n<p>\n        <strong>About\u00a0Wave Life Sciences<\/strong><br \/>\n        <br \/>Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave\u2019s RNA medicines platform, PRISM\u00ae, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave\u2019s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington\u2019s disease, as well as several preclinical programs utilizing the company\u2019s versatile RNA medicines platform. Driven by the calling to \u201cReimagine Possible,\u201d Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave\u2019s science, pipeline and people, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RWtHGMLCU7a7ILGUJCf02rrUUJdM2s_fF2_3brCVL0Ng9NfLWFxXxzZVvM-TytziT1suOutIq648sc7GHebUajuOAedb5FbnqDGg_Fmsmcy4YUnv-tCfKGfKp2MIiPZY\" rel=\"nofollow\" target=\"_blank\">www.wavelifesciences.com<\/a> and follow Wave on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hFu7pxqT4lG-6UKxZ1CLVEvpun1sKX9yYiMOpHfHX4jEKxwvMQZAr4w4yvJmSGtrz5RbJPewMNWkEy3mvdUoiQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q0rwKv9Fsd_9RFGhJuq7Sw1EjkedX_bOVLVr1nhHxsyNeXSHtZ6VLFU9L68yi-RNZLNLYk9FnYuzY7vvdSuUKriH_zQkYgAkFnZvu6gKbj8llrnmhSdTNWbjSGgaytId\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, timing, design, progress, data and announcements related to our clinical trials, including interactions with and feedback from regulators and any potential registrational submissions based on these data; the future performance and results of our programs in clinical trials, including the anticipated therapeutic benefits of such programs and our expectations with respect to how our clinical data may predict success for our future therapeutic candidates and data readouts; the breadth and versatility of our PRISM<sup>\u00ae<\/sup> drug discovery and development platform; and the potential benefits of our RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers). The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. Actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled \u201cRisk Factors\u201d in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings we make with the SEC from time to time. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation, except to the extent required by law, to update the information contained in this press release to reflect subsequently occurring events or circumstances.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Kate Rausch<br \/>VP, Corporate Affairs and Investor Relations<br \/>+1 617-949-4827<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>James Salierno<br \/>Director, Investor Relations<br \/>+1 617-949-4043 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pV_-spp4prn0qAk_zCWb29-qCsHG8mSSha8opMefM6JVCRsTK08etP7rJWo4wesILeicBt5H1f3P568OM-LgnTf4OAPP4Gbpr0rs9O4V_SR_HY8mGnEI3xxolLgK1h2RVf6xMClkrh1hoDxKr4B5HA==\" rel=\"nofollow\" target=\"_blank\">InvestorRelations@wavelifesci.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong>:<br \/>Katie Sullivan<br \/>Senior Director, Corporate Communications<br \/>+1 617-949-2936<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VC-uG7rJQ3tYdDy9V40Dko6wIGap04vFNXX8rUX6uN7mOfnAubXBASC7a0nleBj1rLLZNMkVTwL6-kq18GBuEyrStBUN4_FFSOvnxLyKsVWkiByAcP8a2bL60A0kjjLI\" rel=\"nofollow\" target=\"_blank\">MediaRelations@wavelifesci.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmI5OTIwYmQtOGE5OC00NzdjLTkyMDEtYWEyNmFjYjZlZDdmLTEwMzE4NjAtMjAyNi0wMy0wNS1lbg==\/tiny\/Wave-Life-Sciences-USA-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic Society (ATS) International Conference taking place in Orlando, Florida during May 15-20, 2026. Wave now expects to share data from the 600 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942276","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic Society (ATS) International Conference taking place in Orlando, Florida during May 15-20, 2026. Wave now expects to share data from the 600 &hellip; Continue reading &quot;Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T16:56:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference\",\"datePublished\":\"2026-03-05T16:56:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/\"},\"wordCount\":905,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/\",\"name\":\"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=\",\"datePublished\":\"2026-03-05T16:56:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Market Newsdesk","og_description":"Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic Society (ATS) International Conference taking place in Orlando, Florida during May 15-20, 2026. Wave now expects to share data from the 600 &hellip; Continue reading \"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T16:56:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference","datePublished":"2026-03-05T16:56:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/"},"wordCount":905,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/","name":"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=","datePublished":"2026-03-05T16:56:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjMzOCM3NDY5MDcyIzIwMjAyODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942276"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942276\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}